Tag: Inventiva
Inventiva announces the resumption of screening in the Phase III clinical study, NATiV3, evaluating lanifibranor in NASH – 03/07/2024 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), March 7, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva: falls heavily after the announcements
(Boursier.com) — Inventive drop of 16% this Friday to 3 euros, after having reviewed its accounts and its NATiV3 clinical study. As of December 31, 2023, Inventiva recorded 26.9 million…
Inventiva: After a potential serious effect on a patient, Inventiva must pause its clinical trials
(BFM Bourse) – The stock price of the Burgundy biotechnology firm falls after bad news in the context of a clinical study concerning lanifibranor, its most advanced drug candidate against…
Inventiva publishes its preliminary financial information for the 2023 fiscal year¹ and provides an update on its NATiV3 clinical study – 02/15/2024 at 10:35 p.m.
Daix (France), Long Island City (New York, United States), February 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Half-year review of the liquidity contract of the company Inventiva concluded with Kepler Cheuvreux – 01/24/2024 at 10:11 p.m.
Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva: drawing of 25 ME from the EIB
By Arnaud Bivès Published on 01/11/2024 at 7:51 a.m. (Boursier.com) — Inventive announces the drawing of the second tranche of 25 million…
Inventiva announces the drawing of the second tranche of 25 million euros as part of its Financing Contract with the European Investment Bank – 01/10/2024 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), January 10, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical study and provides an update on its clinical development program – 12/20/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), December 20, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva: 43.8 million euros in cash, visibility expected until mid-2024
(AOF) – Inventiva publishes cash and cash equivalents at 43.8 million euros, compared to 86.7 million euros a year ago. The biotech specializing in the clinical development of small molecules…
Inventiva: financial visibility until the 3rd quarter of 2024
By Alexandra Saintpierre Published on 11/21/2023 at 10:24 p.m. Photo credit © Inventiva (Boursier.com) — The turnover ofInventive…
Inventiva publishes its financial information for the 3rd quarter of 2023 – 11/21/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), November 21, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva announces a late breaker abstract and two additional abstracts on its lead drug candidate, lanifibranor, at the Liver Meeting™ 2023 organized by the AASLD – 11/06/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), November 6, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…